ArticleGene & protein in disease2024
Identification of stress-induced epigenetic methylation onto dopamine D2 gene and neurological and behavioral consequences.
Abstract read
In one paragraph
Article in Gene & protein in disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Unpredictable Chronic Mild Stress Upregulates Dopamine Receptor Expression Independent of Fatty Acid-Binding Protein 7 Gene Deletion.Neurochemical research · 2026Article
- Understanding betel nut addiction: a review of harmful consequences, underlying neurobiology, and emerging intervention strategies.Translational psychiatry · 2026Review
- Beyond Stigma-Integrating Neurobiology, Genetics, and Awareness Integration Theory in Addiction Recovery.Psychology research and behavior management · 2026Article
- Multi-Locus Pro-Dopaminergic Restoration of Reward Brain Circuitry in Reward Deficiency Rescinds Mono-Pharmaceutical Targeting.Neurology (E-Cronicon) · 2025Article
- Is It Scientifically Possible To 'Cure" Reward Deficiency Syndrome (RDS) Via Transplice Molecular Genetic Technology?Acta scientific neurology · 2025Article
- Response to the SAMHSA Clinical Advisory: Considerations for Genetic Testing in the Assessment of Substance Use Disorder Risk.Substance abuse and rehabilitation · 2025Article
- Addictive Behavior and Evolutionary Adaptation: Mitigated through Genetic Addiction Risk Severity Early Identification and Awareness Integration Theory.Medical research archives · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Kenneth BlumDepartment of Molecular Biology, Adelson School of Medicine, Ariel University, Ariel, Israel.
Abdalla BowirratDepartment of Molecular Biology, Adelson School of Medicine, Ariel University, Ariel, Israel.
David BaronDivision of Addiction Research & Education, Center for Sports, Exercise & Mental Health, Western University of the Health Sciences, Pomona, CA, United States of America.
Igor ElmanDivision of Personalized Neuromodulation Research, Sunder Foundation, Palm Springs, CA, United States of America.
Milan T MakaleDepartment of Radiation Medicine and Applied Sciences, UC San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093-0819, United States of America.
Jean Lud CadetMolecular Neuropsychiatry Research Branch, National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD., United States of America.
Panayotis K ThanosBehavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Clinical Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biosciences, State University of New York at Buffalo, Buffalo, NY, United States of America; Department of Psychology, State University of New York at Buffalo, Buffalo, NY., United States of America.
Colin HannaBehavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Clinical Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biosciences, State University of New York at Buffalo, Buffalo, NY, United States of America; Department of Psychology, State University of New York at Buffalo, Buffalo, NY., United States of America.
Rania AhmedBehavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Clinical Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biosciences, State University of New York at Buffalo, Buffalo, NY, United States of America; Department of Psychology, State University of New York at Buffalo, Buffalo, NY., United States of America.
Marjorie C Gondre-LewisDepartment of Anatomy, Howard University College of Medicine, and Developmental Neuropsychopharmacology Laboratory, Howard University College of Medicine, Washington D.C., United States of America.
Catherine A DennenDepartment of Family Medicine, Jefferson Health Northeast, Philadelphia, PA, United States of America.
Eric R BravermanDivision of Nutrigenomics, The Kenneth Blum Behavioral Neurogenetic Institute, Austin, TX United States of America.
Diwanshu SoniDivision of Addiction Research & Education, Center for Sports, Exercise & Mental Health, Western University of the Health Sciences, Pomona, CA, United States of America.
Paul CarneyDivision Pediatric Neurology, University of Missouri, School of Medicine, Columbia, MO., United States of America.
Jag KhalsaDepartment of Microbiology, Immunology and Tropical Medicine, George Washington University, School of Medicine and Health Sciences, Washington, DC, United States of America.
Edward J ModestinoDepartment of Psychology, Curry College, Milton, MA., United States of America.
Debmalya BarhCentre for Genomics and Applied Gene Technology, Institute of Integrative Omics and Applied Biotechnology, Nonakuri, Purba Medinipur, West Bengal, India.
Debasis BagchiDepartment of Pharmaceutical Sciences, Texas Southern University College of Pharmacy and Health Sciences, Houston, TX, United States of America.
Rajendra D BadgaiyanDepartment of Psychiatry, Case Western Reserve University School of Medicine, Cleveland OH., 44106, USA and Department of Psychiatry, Mt. Sinai School of Medicine, New York, NY, United States of America.
Thomas McLaughlinDivision of Nutrigenomics, The Kenneth Blum Behavioral Neurogenetic Institute, Austin, TX United States of America.
Rene CorteseDepartment of Child Health - Child Health Research Institute, & Department of Obstetrics, Gynecology and Women's Health School of Medicine, University of Missouri, MO, United States of America.
Mauro CeccantiAlcohol Addiction Program, Latium Region Referral Center, Sapienza University of Rome, Roma, Italy.
Kevin T MurphyDivision of Personalized Neuromodulation and Patient Care, PeakLogic, LLC, Del Mar, CA, United States of America.
Ashim GuptaFuture Biologics, Lawrenceville, Georgia, 30043, United States of America.
Miles T MakaleDepartment of Psychology, UC San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093-0819, United States of America.
Keerthy SunderDivision of Personalized Neuromodulation Research, Sunder Foundation, Palm Springs, CA, United States of America.
Mark S GoldDepartment of Psychiatry, Washington University School of Medicine, St. Louis, MO, United States of America.
Funding
Dopamine Neurotransmission in AddictionI01CX000479 · VA · VA WESTERN NEW YORK HEALTHCARE SYSTEM · PI BADGAIYAN, RAJENDRA D · 2013 to 2014
–CSRD VA I01 CX000479
Abstract
The D2 dopamine receptor (
Indexed as
Dopamine D2 receptorEpigenetic modificationNeurological disordersStress
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.